Pulmonary Hypertension in Parenchymal Lung Disease

Rosechelle M. Ruggiero; Sonja Bartolome; Fernando Torres

doi:10.1016/j.hfc.2012.04.010

Pulmonary Hypertension in Parenchymal Lung Disease

Rosechelle M. Ruggiero, Sonja Bartolome, Fernando Torres

Research output: Contribution to journal › Review article

9 Scopus citations

Abstract

The pathophysiology of pulmonary hypertension (PH) in parenchymal lung diseases is partially related to hypoxic pulmonary vasoconstriction. PH treatment is controversial for these patients. This article focuses on group III PH, namely PH attributable to lung diseases and/or hypoxia. Group III includes chronic obstructive pulmonary disease and interstitial lung diseases, the most common parenchymal lung diseases associated with PH. It also includes sleep-disordered breathing and hypoventilation from any cause. Other parenchymal lung diseases associated with PH, namely sarcoidosis and systemic vasculitides (group V), are discussed. The data describing PH in specific parenchymal diseases are reviewed.

Original language	English (US)
Pages (from-to)	461-474
Number of pages	14
Journal	Heart Failure Clinics
Volume	8
Issue number	3
DOIs	https://doi.org/10.1016/j.hfc.2012.04.010
State	Published - Jul 1 2012

Keywords

Chronic obstructive pulmonary disease
Idiopathic pulmonary fibrosis
Interstitial lung disease
Pulmonary hypertension

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.hfc.2012.04.010

Fingerprint Dive into the research topics of 'Pulmonary Hypertension in Parenchymal Lung Disease'. Together they form a unique fingerprint.

Cite this

Ruggiero, R. M., Bartolome, S., & Torres, F. (2012). Pulmonary Hypertension in Parenchymal Lung Disease. Heart Failure Clinics, 8(3), 461-474. https://doi.org/10.1016/j.hfc.2012.04.010

@article{e338d3ae8c68485697e6dc4afa694222,

title = "Pulmonary Hypertension in Parenchymal Lung Disease",

abstract = "The pathophysiology of pulmonary hypertension (PH) in parenchymal lung diseases is partially related to hypoxic pulmonary vasoconstriction. PH treatment is controversial for these patients. This article focuses on group III PH, namely PH attributable to lung diseases and/or hypoxia. Group III includes chronic obstructive pulmonary disease and interstitial lung diseases, the most common parenchymal lung diseases associated with PH. It also includes sleep-disordered breathing and hypoventilation from any cause. Other parenchymal lung diseases associated with PH, namely sarcoidosis and systemic vasculitides (group V), are discussed. The data describing PH in specific parenchymal diseases are reviewed.",

keywords = "Chronic obstructive pulmonary disease, Idiopathic pulmonary fibrosis, Interstitial lung disease, Pulmonary hypertension",

author = "Ruggiero, {Rosechelle M.} and Sonja Bartolome and Fernando Torres",

year = "2012",

month = jul,

day = "1",

doi = "10.1016/j.hfc.2012.04.010",

language = "English (US)",

volume = "8",

pages = "461--474",

journal = "Heart Failure Clinics",

issn = "1551-7136",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Pulmonary Hypertension in Parenchymal Lung Disease

AU - Ruggiero, Rosechelle M.

AU - Bartolome, Sonja

AU - Torres, Fernando

PY - 2012/7/1

Y1 - 2012/7/1

N2 - The pathophysiology of pulmonary hypertension (PH) in parenchymal lung diseases is partially related to hypoxic pulmonary vasoconstriction. PH treatment is controversial for these patients. This article focuses on group III PH, namely PH attributable to lung diseases and/or hypoxia. Group III includes chronic obstructive pulmonary disease and interstitial lung diseases, the most common parenchymal lung diseases associated with PH. It also includes sleep-disordered breathing and hypoventilation from any cause. Other parenchymal lung diseases associated with PH, namely sarcoidosis and systemic vasculitides (group V), are discussed. The data describing PH in specific parenchymal diseases are reviewed.

AB - The pathophysiology of pulmonary hypertension (PH) in parenchymal lung diseases is partially related to hypoxic pulmonary vasoconstriction. PH treatment is controversial for these patients. This article focuses on group III PH, namely PH attributable to lung diseases and/or hypoxia. Group III includes chronic obstructive pulmonary disease and interstitial lung diseases, the most common parenchymal lung diseases associated with PH. It also includes sleep-disordered breathing and hypoventilation from any cause. Other parenchymal lung diseases associated with PH, namely sarcoidosis and systemic vasculitides (group V), are discussed. The data describing PH in specific parenchymal diseases are reviewed.

KW - Chronic obstructive pulmonary disease

KW - Idiopathic pulmonary fibrosis

KW - Interstitial lung disease

KW - Pulmonary hypertension

UR - http://www.scopus.com/inward/record.url?scp=84863088716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863088716&partnerID=8YFLogxK

U2 - 10.1016/j.hfc.2012.04.010

DO - 10.1016/j.hfc.2012.04.010

M3 - Review article

C2 - 22748906

AN - SCOPUS:84863088716

VL - 8

SP - 461

EP - 474

JO - Heart Failure Clinics

JF - Heart Failure Clinics

SN - 1551-7136

IS - 3

ER -